key: cord-0279150-x0vh1vdl authors: Ainslie, K. E. C.; Backer, J. A.; de Boer, P.; van Hoek, A. J.; Klinkenberg, D.; Korthals Altes, H.; Leung, K. Y.; de Melker, H.; Miura, F.; Wallinga, J. title: The impact of vaccinating adolescents and children on COVID-19 disease outcomes date: 2021-10-25 journal: nan DOI: 10.1101/2021.10.21.21265318 sha: 38ded977cd7c2227d901d5a505adf2e7a6d16636 doc_id: 279150 cord_uid: x0vh1vdl Introduction: Despite the high COVID-19 vaccination coverage among adults, there is concern over a peak in SARS-CoV-2 infections in the coming months. To help ensure that healthcare systems are not overwhelmed in the event of a new wave of SARS-CoV-2 infections, many countries have extended vaccination to adolescents (those aged 12-17 years) and may consider further extending to children aged 5-11 years. However, there is considerable debate about whether or not to vaccinate healthy adolescents and children against SARS-CoV-2 because, while vaccination of children and adolescents may limit transmission from these groups to other, more vulnerable groups, adolescents and children themselves have limited risk of severe disease if infected and may experience adverse events from vaccination. To quantify the benefits of extending COVID-19 vaccination beyond adults we compare daily cases, hospital admissions, and intensive care (IC) admissions for vaccination in adults only, those 12 years and above, and those 5 years and above. Methods and Findings: We developed a deterministic, age-structured susceptible-exposed-infectious-recovered (SEIR) model to simulate disease outcomes (e.g., cases, hospital admissions, IC admissions) under different vaccination scenarios. The model is partitioned into 10-year age bands (0-9, 10-19, ..., 70-79, 80+) and accounts for differences in susceptibility and infectiousness by age group, seasonality in transmission rate, modes of vaccine protection (e.g., infection, transmission), and vaccine characteristics (e.g., vaccine effectiveness). Model parameters are estimated by fitting the model piecewise to daily cases from the Dutch notification database Osiris from 01 January 2020 to 22 June 2021. Forward simulations are performed from 22 June 2021 to 31 March 2022. We performed sensitivity analyses in which vaccine-induced immunity waned. We found that upon relaxation of all non-pharmaceutical control measures a large wave occurred regardless of vaccination strategy. We found overall reductions of 5.7% (4.4%, 6.9%) of cases, 2.0% (0.7%, 3.2%) of hospital admissions, and 1.7% (0.6%, 2.8%) of IC admissions when those 12 years and above were vaccinated compared to vaccinating only adults. When those 5 years and above were vaccinated we observed reductions of 8.7% (7.5%, 9.9%) of cases, 3.2% (2.0%, 4.5%) of hospital admissions, and 2.4% (1.2%, 3.5%) of IC admissions compared to vaccination in adults only. Benefits of extending vaccination were larger within the age groups included in the vaccination program extension than in other age groups. The benefits of vaccinating adolescents and children were smaller if vaccine protection against infection, hospitalization, and transmission (once infected) wanes. Discussion: Our results highlight the benefits of extending COVID-19 vaccination programs beyond adults to reduce infections and severe outcomes in adolescents and children and in the wider population. A reduction of infections in school-aged children/adolescents may have the added benefit of reducing the need for school closures during a new wave. Additional control measures may be required in future to prevent a large wave despite vaccination program extensions. While the results presented here are based on population characteristics and the COVID-19 vaccination program in The Netherlands, they may provide valuable insights for other countries who are considering COVID-19 vaccination program extensions. ] . T h e r e f o r e , v a c c i n a t i o n o f t h i s g r o u p m a y h a v e h i g h e r d i r e c t b e n e f i t s i n t e r m s o f a c c e s s t o e d u c a t i o n a n d m e n t a l w e l l -b e i n g [ 2 1 ] . A n o t h e r o b j e c t i v e f o r v a c c i n a t i n g a d o l e s c e n t s i s t o r e d u c e t r a n s m i s s i o n f r o m t h i s g r o u p t o o t h e r , m o r e v u l n e r a b l e , g r o u p s . A d o l e s c e n t s m a k e a h i g h n u m b e r o f d a i l y c o n t a c t s [ 3 8 -4 0 ] a n d h a v e l o w e r a d h e r e n c e t o n o n -p h a r m a c e u t i c a l i n t e r v e n t i o n s [ 4 1 ] . T h e r e f o r e , t h i s g r o u p i s l i k e l y t o b e a l a r g e c o n t r i b u t o r t o t r a n s m i s s i o n i n t h e e v e n t o f l a r g e o u t b r e a k s , a s w a s s e e n i n l a t e J u n e a n d e a r l y J u l y i n t h e N e t h e r l a n d s [ 4 2 ] . I n t h e U n i t e d K i n g d o m , a n i n c r e a s e i n i n f e c t i o n s i n a d o l e s c e n t s a n d y o u n g a d u l t s p r e c e d e d t h e s e c o n d a n d t h i r d w a v e s , w h e r e i n f e c t i o n s l a t e r s p r e a d t o o l d e r a g e g r o u p s [ 4 3 -4 6 ] . a t a o n v a c c i n e e f f e c t i v e n e s s a g a i n s t t r a n s m i s s i o n i n a d o l e s c e n t s i s c u r r e n t l y l a c k i n g , s t u d i e s h a v e s h o w n t h a t h o u s e h o l d m e m b e r s o f v a c c i n a t e d a d u l t s w e r e a t r e d u c e d r i s ] . I f v a c c i n a t i o n o f a d o l e s c e n t s p r o v i d e s s i m i l a r p r o t e c t i o n a g a i n s t t r a n s m i s s i o n t o h o u s e h o l d m e m b e r s , t h e n v a c c i n a t i o n m a y b e a u s e f u l t o o l t o r e d u c e t r a n s m i s s i o n f r o m a d o l e s c e n t s t o o t h e r g r o u p s . A s w i t h a d o l e s c e n t s , c h i l d r e n a r e a t a r e d u c e d r i s k o f s e v e r e d i s e a s e a f t e r i n f e c t i o n w i t h S A R S -C o V -2 [ 2 3 -2 5 ] . H o w e v e r , v a c c i n a t i o n o f c h i l d r e n m a y r e d u c e t r a n s m i s s i o n o f S A R S -C o V -2 i n t h e w i d e r p o p u l a t i o n , a s h a s b e e n s h o w n i n t h e c o n t e x t o f i n f l u e n z a [ 5 0 ] . P r i o r C O V I D -1 9 m o d e l l i n g w o r k h a s s h o w n t h a t h i g h i n c i d e n c e o f S A R S -C o V -2 i n f e c t i o n s m a y b e e x p e c t e d i f c h i l d r e n a r e n o t v a c c i n a t e d a n d t h a t t h i s w i l l c o n t r i b u t e t o i n f e c t i o n s i n u n p r o t e c t e d a d u l t s [ 5 1 , 5 2 ] . T h e r e f o r e , f e w e r n o n -p h a r m a c e u t i c a l i n t e r v e n t i o n s , s u c h a s s c h o o l c l o s u r e s , w o u l d b e r e q u i r e d t o c o n t r o l i n f e c t i o n r a t e s i f c h i l d r e n w e r e a l s o i n c l u d e d i n t h e v a c c i n a t i o n p r o g r a m [ 5 2 ] . L i t t l e e v i d e n c e h a s b e e n p u b l i s h e d t h u s f a r a b o u t t h e e f f e c t s o f v a c c i n a t i n g a d o l e s c e n t s o r f u r t h e r e x t e n d i n g C O V I D -1 9 v a c c i n a t i o n p r o g r a m s t o i n c l u d e c h i l d r e n . I n t h i s w o r k , w e q u a n t i f y t h e i m p a c t s o f e x t e n d i n g C O V I D -1 9 v a c c i n a t i o n b e y o n d a d u l t s u s i n g a d e t e r m i n i s t i c , a g e -s t r u c t u r e d s u s c e p t i b l e -e x p o s e d -i n f e c t i o u s -r e c o v e r e d ( S E I R ) m o d e l . O u r a p p r o a c h w a s p r e v i o u s l y u s e d t o i n f o r m v a c c i n a t i o n p o l i c y r e g a r d i n g t h e v a c c i n a t i o n o f 1 2 -1 7 y e a r o l d s i n T h e N e t h e r l a n d s [ 1 6 , 3 3 ] b e f o r e t h e e m e r g e n c e o f t h e D e l t a v a r i a n t . W e t h e r e f o r e u s e t h e N e t h e r l a n d s a s o u r m o t i v a t i n g e x a m p l e . H e r e , w e p r e s e n t u p d a t e d a n a l y s e s u s i n g m o d e l p a r a m e t e r s c o n s i s t e n t w i t h t h e D e l t a v a r i a n t . W e q u a n t i f i e d t h e i m p a c t s o f v a c c i n a t i n g a d o l e s c e n t s ( 1 2 -1 7 y e a r s o l d s ) a n d a d o l e s c e n t s a n d c h i l d r e n ( 5 -1 7 y e a r o l d s ) o n d i s e a s e o u t c o m e s ( e . g . , c a s e s , h o s p i t a l a d m i s s i o n s , a n d I C a d m i s s i o n s ) . W e c o m p a r e d i s e a s e o u t c o m e s i n e x t e n d e d v a c c i n a t i o n s c e n a r i o s . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; W e a s s u m e v a c c i n a t i o n o f c h i l d r e n a n d a d o l e s c e n t s d o e s n o t i m p a c t t h e c o n t i n u e d v a c c i n a t i o n o f o t h e r g r o u p s . I n t h e s c e n a r i o i n w h i c h 1 2 -1 7 y e a r o l d s a r e v a c c i n a t e d ( 1 2 + ) , w e a s s u m e t h e y r e c e i v e t h e v a c c i n e s m a d e b y P f i z e r / B i o N T e c h a n d M o d e r n a b e g i n n i n g 2 2 J u n e 2 0 2 1 a n d r e a c h a n o v e r a l l c o v e r a g e o f 7 5 % b y 2 3 A u g u s t 2 0 2 1 a s p e r t h e D u t c h v a c c i n a t i o n d i s t r i b u t i o n s c h e d u l e ( F i g u r e S 3 ) . W h e n w e e x t e n d v a c c i n a t i o n t o 5 -1 1 y e a r o l d s ( 5 + ) , w e a s s u m e a f i n a l v a c c i n a t i o n c o v e r a g e o f 7 d u c t i o n i n I C a d m i s s i o n s i n t h e e n t i r e p o p u l a t i o n c o m p a r e d t o v a c c i n a t i o n i n a d u l t s o n l y ( T a b l e 1 ) . T h e s e p e r c e n t r e d u c t i o n s c o r r e s p o n d e d t o a b s o l u t e r e d u c t i o n s o f 2 2 0 6 4 6 ( 1 8 3 3 5 3 , 2 5 7 9 9 5 ) c a s e s , 1 4 5 4 ( 8 5 5 , 2 0 5 5 ) h o s p i t a l a d m i s s i o n s , a n d 2 2 6 ( 1 1 4 , 3 3 7 ) I C a d m i s s i o n s . A s w i t h t h e 1 2 + s c e n a r i o , b e n e f i t s w e r e l a r g e r w i t h i n T a b l e 2 ) . I C a d m i s s i o n s i n t h e e n t i r e p o p u l a t i o n , b u t t h a t p e r c e n t r e d u c t i o n s i n d i s e a s e o u t c o m e s w e r e l a r g e r i n t h e 1 0 -1 9 a g e g r o u p a g e g r o u p ( 2 2 . 5 % o f c a s e s , 2 2 . 5 % o f h o s p i t a l a d m i s s i o n s , a n d 3 6 . 0 % o f I C a d m i s s i o n s ) . W h e n v a c c i n a t i o n w a s e x t e n d e d f u r t h e r t o i n c l u d e 5 -1 1 y e a r o l d s , w e o b s e r v e d o v e r a l l r e d u c t i o n s o f . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. I n c o n c l u s i o n , o u r r e s u l t s h i g h l i g h t t h e b e n e f i t s t o e x t e n d i n g C O V I D -1 9 v a c c i n a t i o n p r o g r a m s t o c h i l d r e n a n d a d o l e s c e n t s t o r e d u c e i n f e c t i o n s a n d s e v e r e o u t c o m e s , b o t h i n c h i l d r e n a n d a d o l e s c e n t s t h e m s e l v e s a n d i n t h e p o p u l a t i o n a s a w h o l e . H o w e v e r , e x t e n d i n g v a c c i n a t i n g a l o n e w i l l n o t p r e v e n t a f u t u r e e p i d e m i c . T h e r e f o r e , a d d i t i o n a l c o n t r o l m e a s u r e s m a y n e e d t o b e i m p l e m e n t e d t o p r e v e n t a l a r g e i n c r e a s e i n h o s p i t a l a n d I C a d m i s s i o n s . W h i l e t h e r e s u l t s p r e s e n t e d h e r e a r e b a s e d o n p o p u l a t i o n c h a r a c t e r i s t i c s a n d t h e C O V I D -1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) ( -1 1 1 , . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint T a b l e 2 . C u m u l a t i v e s u m , a b s o l u t e d i f f e r e n c e , a n d p e r c e n t d i f f e r e n c e o f m o d e l l e d o u t c o m e s b y v a c c i n a t i o n s c e n a r i o ( 1 8 + , 1 ( -8 6 , ( -1 3 9 3 , . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; p r o d u c t s c u r r e n t l y l i c e n s e d f o r u s e a g a i n s t C O V I D -1 9 i n T h e N e t h e r l a n d s ( t h e v a c c i n e s m a d e b y P f i z e r / B i o N T e c h , M o d e r n a , A s t r a Z e n e c a , a n d J a n s s e n ) , w e i n c o r p o r a t e d i f f e r e n t v a c c i n e p r o d u c t s b y t a k i n g t h e d a i l y w e i g h t e d a v e r a g e o f t h e n u m b e r o f p e o p l e w i t h e a c h v a c c i n e p r o d u c t ( a n d d o s e ) , t h e c o r r e s p o n d i n g d e l a y t o p r o t e c t i o n o f e a c h v a c c i n e p r o d u c t , a n d t h e v a c c i n e e f f e c t i v e n e s s a g a i n s t e a c h o u t c o m e ( T a b l e S 1 ) . J a n s s e n i s i n c o r p o r a t e d b y u s i n g z e r o f o r t h e n u m b e r o f s e c o n d d o s e s a t a l l t i m e p o i n t s . T h I t w a s a s s u m e d t h a t a v a i l a b l e v a c c i n e s w e r e a d m i n i s t e r e d i m m e d i a t e l y u n t i l a t a r g e t g r o u p r e a c h e d t h e f i n a l c o v e r a g e . T o a c c o u n t f o r t h e s e a s o n a l p a t t e r n o f S A R S -C o V -2 w h e r e b y , t r a n s m i s s i o n i s l o w e r i n s u m m e r a n d h i g h e r i n w i n t e r , w e d e f i n e t h e t r a n s m i s s i o n r a t e a t t i m . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; m u l t i p l y i n g t h e r o w s a n d c o l u m n s o f t h e c o n t a c t m a t r i x b y e s t i m a t e s o f t h e r e l a t i v e s u s c e p t i b i l i t y a n d i n f e c t i o u s n e s s o f e a c h a g e g r o u p c o m p a r e d t o t h e 0 -9 y e a r s a g e g r o u p ( T a b l e S 4 ) . T h e a m p l i t u d e o f s e a s o n a l f o r c i n g ߚ ଵ i s e s t i m a t e d b y l i n e a r r e g r e s s i o n : . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. O u r a p p r o a c h w a s u s e d t o i n f o r m D u t c h C O V I D -1 9 p o l i c y r e g a r d i n g t h e v a c c i n a t i o n o f 1 2 -1 7 y e a r o l d s p r i o r t o t h e e m e r g e n c e o f t h e D e l t a v a r i a n t . F o r t h e s e s i m u l a t i o n s , f o r w a r d s i m u l a t i o n s w e r e p e r f o r m e d f r o m 2 2 J u n e 2 0 2 1 t o 3 1 M a r c h 2 0 2 2 w i t h t h e i n i t i a l c o n d i t i o n s ( i . e . , t h e n u m b e r o f p e o p l e i n e a c h c o m p a r t m e n t w h e n t h e s i m u l a t i o n b e g i n s ) b a s e d o n t h e l a s t d a y o f t h e m o d e l f i t t i n g . W e a s s u m e t h e s i m u l a t i o n s b e g i n w i t h t h e s a m e β 0 t h a t w a s e s t i m a t e d f r o m t h e l a s t f i t t e d t i m e w i n d o w ( 0 5 J u n e t o 2 2 J u n e ) a n d w i t h c o n t a c t p a t t e r n s e s t i m a t e d d u r i n g J u n e 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; T a b l e S 2 . T i m e l i n e o f m e a s u r e s a n d a d v i c e d u r i n g t h e C O V I D -1 9 o u t b r e a k i n t h e N e t h e r l a n d s . D a t e C o n t r o l M e a s u r e s 1 6 / 3 / 2 0 2 0 1 . 5 m e t e r s d i s t a n c e r u l e b e g i n s A l l r e s t a u r a n t s a n d b a r s a r e c l o s e d S p o r t / f i t n e s s c l u b s , s a u n a s , s e x c l u b s a n d c o f f e e s h o p s a r e c l o s e d S c h o o l s a n d d a y c a r e f a c i l i t i e s a r e c l o s e d . 2 3 D a t e C o n t r o l M e a s u r e s C a n r e c e i v e a m a x i m u m o f 2 p e o p l e a t h o m e p e r d a y . O u t d o o r t e r r a c e s o p e n f r o m 1 2 : 0 0 t o 1 8 : 0 0 w i t h m a x i m u m o c c u p a n c y o f 5 0 g u e s t s a t 1 . 5 m e t e r d i s t a n c e R e t a i l s t o r e s r e -o p e n f o r w a l k -i n s h o p p i n g ( n o r e s e r v a t i o n n e e d e d ) 1 9 -5 -2 0 2 1 F r o m t h e a g e o f 2 7 s p o r t s o u t s i d e i n g r o u p s a l l o w e d a t a d i s t a n c e o . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; T a b l e S 4 . A g e -d e p e n d e n t m o d e l p a r a m e t e r s . P a r a m e t e r D e s c r i p t i o n A g e g r o u p V a l u e D e t a i l s R a t e f r o m i n f e c t i o u s t o h o s p i t a l 0 -9 0 . 0 0 1 5 C a l c u l a t e d a s t h e p r o b a b i l i t y o f i n f e c t i o n t o h o s p i t a l d i v i d e d b y t i m e f r o m s y m p t o m s t o h o s p i t P a r a m e t e r D e s c r i p t i o n A g e g r o u p V a l u e D e t a i l s 8 0 + 0 . 0 2 9 0 R a t e o f r e c o v e r y f r o m h o s p i t a l ( b e f o r e I C ) 0 -9 0 . 1 2 6 3 C a l c u l a t e d a s 1 -t h e p r o b a b i l i t y o f d e a t h f r o m h o s p i t a l a d m i s s i o n s d i v i d e d b y t h e a v e r a g e t i m e f r o m h o s p i t a l a d m i s s i o n t o d i s c h a r g e ( 7 . 9 d a y s ) 1 0 -1 9 0 . 1 2 6 0 2 0 -2 9 0 . 1 2 5 4 3 0 -3 9 0 . 1 2 3 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 25, 2021. ; Pfizer-BioNTech COVID-19 Vaccine EUA Letter of Authorization Spikevax (previously COVID-19 mRNA Vaccine Moderna): European public assessment report (EPAR) -Medicine Overview Comirnaty European public assessment report (EPAR) -Medicine overview Pfizer asks F.D.A. to authorize its COVID-19 vaccine for children 5 to 11 Seasonal variation in SARS-CoV-2 transmission in temperate climates The role of seasonality in the spread of COVID-19 pandemic Role of air temperature and humidity in the transmission of SARS-CoV-2 in the United States. medRxiv Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Effectiveness of COVID-19 vaccines against variants of concern in Ontario SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight Coronavirus Pandemic (COVID-19). 2020, OurWorldInData.org Advice: Vaccination of adolescents against COVID-19 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Recommendations on the use of COVID-19 Vaccines COVID-19 Vaccines for Children and Teens JCVI issues advice on COVID-19 vaccination of children and young people European Centre for Disease Prevention and Control (ECDC), Interim public health considerations for COVID-19 vaccination of adolescents in the COVID-19 in children and the role of school settings in transmission -first update Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data Children and young people remain at low risk of COVID-19 mortality. The Lancet Child & Adolescent Health Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination Preliminary evidence on long COVID in children Case report and systematic review suggest that children may experience similar longterm effects to adults after clinical COVID-19 Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study The Expected Outcome of COVID-19 Vaccination Strategies Hospitalization of Adolescents Aged 12-17 Years with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States Learning loss due to school closures during the COVID-19 pandemic Impacts of school closures on physical and mental health of children and young people: a systematic review Impact of physical distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Netherlands Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China Social contacts and mixing patterns relevant to the spread of infectious diseases Trajectories of compliance with COVID-19 related guidelines: longitudinal analyses of 50,000 UK adults Resurgence of SARS-CoV-2: Detection by community viral surveillance SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic Coronavirus (COVID-19) Infection Survey Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands Impact of vaccination on household transmission of SARS-CoV-2 Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures Non-pharmaceutical interventions and vaccinating school children required to contain SARS-CoV-2 Delta variant outbreaks in Australia: a modelling analysis Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands PIENTER Corona Study The calendar of epidemics: Seasonal cycles of infectious diseases Absolute humidity modulates influenza survival, transmission, and seasonality Absolute Humidity and the Seasonal Onset of Influenza in the Continental United States Environmental Drivers of the Spatiotemporal Dynamics of Respiratory Syncytial Virus in the United States R: A Language and Environment for Statistical Computing. 2020, R Foundation for Statistical Computing Solving Differential Equations in R: Package deSolve Pfizer and BioNTech announce positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years Loss of childcare and classroom teaching during the Covid-19-related lockdown in spring 2020: A longitudinal study on consequences on leisure behavior and schoolwork at home Fourth meeting of the Technical Advisory Group on Safe Schooling during the COVID-19 Pandemic Genomic evidence for reinfection with SARS-CoV-2: a case study. The Lancet Infectious Diseases Most young people want to be vaccinated Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious Diseases Figures on the COVID-19 vaccination programme. COVID-19 Vaccination How calculation models contribute to the fight against COVID-19 The Royal Netherlands Meteorological Institute (KNMI) Pathogen Surveillance. COVID-19 Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19. medRxiv Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. preprint Effectiveness of the COVID-19 vaccines. Efficacy and protection Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2)